| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $169,643,829 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 4 | NIH | 1/20/2026 | $426,474 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA276779 | Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy | 001 | 5 | NIH | 6/30/2026 | $417,352 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 4 | NIH | 2/27/2026 | $395,807 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI192472 | Dissecting a New Pyroptotic Mechanism Driven by Gasdermin A Activation | 000 | 1 | NIH | 7/9/2026 | $577,181 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA293160 | Evaluating Dietary Change and a Mediterranean Diet Intervention Among Medically Underserved Men with Prostate Cancer | 000 | 2 | NIH | 6/30/2026 | $209,909 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P01CA296429 | Mechanisms of Bladder Cancer Development and Its Therapeutic Vulnerabilities to Preventive and Interventive Therapy. | 000 | 2 | NIH | 8/25/2026 | $2,005,189 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 4 | NIH | 2/27/2026 | $480,324 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 2 | NIH | 3/3/2026 | $676,584 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 001 | 6 | NIH | 4/16/2026 | $40,867 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 6 | NIH | 1/28/2026 | $367,804 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA305986 | Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy | 000 | 2 | NIH | 8/6/2026 | $616,715 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI192499 | TCR-antigen foundation model to empower TCR-based diagnostics and therapeutics | 000 | 2 | NIH | 8/20/2026 | $512,157 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P01CA278716 | InHANCE: Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery | 002 | 2 | NIH | 9/2/2026 | $2,326,624 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA303068 | Study of a new driver and therapeutic vulnerability of bone metastasis | 000 | 2 | NIH | 5/12/2026 | $564,695 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03NS145168 | Investigation of the cell of origin and evolutionary trajectories of human glioblastoma | 000 | 2 | NIH | 7/27/2026 | $81,750 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE034406 | Ontology-based aPplications of mUlti-discipLinary knowlEdge on orodeNtal Conditions and outcomEs (OPULENCE) | 001 | 2 | NIH | 7/7/2026 | $736,507 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25CA181004 | MD Anderson Science Park Summer Program in Cancer Research SPCR | 000 | 12 | NIH | 5/5/2026 | $242,094 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA307194 | Proline tRNA biogenesis as oncogenic drivers and therapeutic target in T cell acute lymphoblastic leukemia | 000 | 1 | NIH | 4/9/2026 | $473,372 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM159819 | Statistical methods to delineate the spatial and temporal pattern of cell-cell interactions in Spatial Transcriptomics data | 000 | 2 | NIH | 8/13/2026 | $449,625 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA303638 | Efficient Measurement and Characterization of Genetic Interactions in Cancer Cells | 000 | 2 | NIH | 7/27/2026 | $370,173 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA294088 | Decipher dose accumulation for online adaptive radiotherapy | 000 | 1 | NIH | 8/31/2026 | $425,410 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA311472 | Disrupting ATF3/CGRP-IL-6 Neuroimmune Feedback to Overcome Neural Injury–Driven Immunotherapy Resistance in cSCC | 000 | 1 | NIH | 7/3/2026 | $645,865 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299430 | Strategic Modulation of Liver Phenylalanine Metabolism and Neutrophil Kainate Receptor to Influence the Tumor Macroenvironment: Mechanisms and Preclinical Strategies | 000 | 1 | NIH | 9/7/2026 | $702,683 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA308995 | Efficacy of an inpatient yoga therapy program for cancer patients undergoing hematopoietic stem cell transplantation | 000 | 1 | NIH | 9/10/2026 | $678,525 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K00CA294065 | Metabolic Reprogramming of Myeloid Cells to Enhance Cancer Immunotherapy | 000 | 3 | NIH | 9/10/2026 | $98,136 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01DK141967 | Multi-omic approaches to exploring the gut microbiome and metabolic dysfunction-associated steatotic liver disease (MASLD) | 000 | 1 | NIH | 3/10/2026 | $151,136 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21ES039048 | Identifying PFAS-Induced Disruption of Placental Imprinting and Neurodevelopment Through Multi-Omic Negative Control Calibration | 000 | 1 | NIH | 9/9/2026 | $241,317 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA297013 | Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy | 000 | 3 | NIH | 9/2/2026 | $249,000 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA317445 | Joy Luck Virtual Academy (JOY): A Culturally Centered Intervention | 000 | 1 | NIH | 9/4/2026 | $642,129 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K23HL186120 | Advancing Sustainable Obesity Care: Integrating Food is Medicine with GLP-1 Receptor Agonists | 000 | 1 | NIH | 9/3/2026 | $103,684 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K00CA294259 | An-in-depth exploration of coping strategies and their impact on psychological distress in cancer survivors | 000 | 3 | NIH | 9/8/2026 | $98,136 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U24CA294136 | Enabling functional multimodal characterization of cancer evolution from single-cell data | 000 | 1 | NIH | 9/7/2026 | $813,295 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61AG102807 | Development of a Nonhuman Primate Infrastructure for Interdisciplinary Research on Perimenopause and Aging | 000 | 1 | NIH | 9/2/2026 | $628,988 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI192331 | Reversing effector-to-memory transition at ARTi to impact the HIV reservoir towards ART-free control | 000 | 2 | NIH | 8/13/2026 | $1,031,799 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL178867 | Dissect the consequences of telomere stress on hematopoietic stem cells | 001 | 1 | NIH | 7/17/2026 | $808,607 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL178867 | Dissect the consequences of telomere stress on hematopoietic stem cells | 000 | 1 | NIH | 4/24/2026 | $819,998 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA296416 | Deciphering the role of cancer pain-associated neuronal activity in driving malignancies | 000 | 2 | NIH | 8/21/2026 | $482,854 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS143931 | Acid-Sensing Ion Channel 1a Regulates Synapse-Glioblastoma Integration | 000 | 1 | NIH | 7/8/2026 | $633,653 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA316981 | The role of tertiary lymphoid structures in brain tumor therapy with oncolytic adenoviruses | 000 | 1 | NIH | 9/1/2026 | $421,685 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM165366 | Dissecting the role of extracellular vesicles and matrix in wound healing | 000 | 1 | NIH | 8/25/2026 | $451,000 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HG014774 | Statistical Methods for 3-Dimensional Spatial Transcriptomics: Design, Imputation, and Analysis | 000 | 1 | NIH | 7/6/2026 | $2,759,668 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA313246 | Osteosarcoma-specific glycoforms of CD24 | 000 | 1 | NIH | 7/6/2026 | $164,000 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA311111 | Lineage plasticity sensitizes FGFR3-mutant bladder cancer to FGFR inhibitors | 000 | 1 | NIH | 6/23/2026 | $637,473 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA307136 | Spatial and functional profiling tumor evolution trajectories and microenvironment interactions of VHL driven renal cancers | 000 | 1 | NIH | 4/10/2026 | $131,933 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA294638 | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome | 001 | 1 | NIH | 7/3/2026 | $0 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA294638 | Assessment of Immune Responses to Neoantigen Vaccination in Lynch Syndrome | 000 | 1 | NIH | 6/30/2026 | $696,924 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA303784 | Secreted peptides as biomarkers and effectors of neuroendocrine transformation | 000 | 1 | NIH | 8/5/2026 | $192,224 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM164196 | Ion channel regulation by auxiliary proteins | 000 | 1 | NIH | 7/7/2026 | $451,000 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31HG015198 | A functional multi-omics approach to identify HSP90-buffered genetic variation | 000 | 1 | NIH | 8/12/2026 | $38,283 |
|
